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Context: Gonadectomy is avoided whenever possible in boys with 45,X/46,XY. However, no clinical
markers are currently available to guide clinicians in predicting gonadal tumor risk or hormone
production.
Objective: The objective of the study was to test the hypothesis that gonadal histology and risk for
development of amalignant germ cell tumor are reflectedby the clinical presentationof a 45,X/46,XY
individual.
Design: The design of the studywas the correlation of clinical data [external masculinization score
(EMS), pubertal outcome] with pathology data (gonadal phenotype, tumor risk).
Setting: Thiswas amulticenter study involving twomultidisciplinary disorder of sex development teams.
Patients:Patients includedgeneticallyproven45,X/46,XY (andvariants) cases, ofwhomat leastone
gonadal biopsy or gonadectomy specimen was available, together with clinical details.
Interventions: Patients (n  48) were divided into three groups, based on the EMS. Gonadal
histologyand tumor riskwereassessedonparaffin-embedded samples (n87)bymorphologyand
immunohistochemistry on the basis of established criteria.
MainOutcomeMeasures:Gonadal differentiation and tumor risk in the three clinical groupswere
measured. Clinical outcome in patients with at least one preserved gonad was also measured.
Results: Tumor risk in the three groups was significantly related to the gonadal differentiation
pattern (P 0.001). In boys, hormone productionwas sufficient andwas not predicted by the EMS.
Conclusions: The EMS reflects gonadal differentiation and tumor risk in patients with 45,X/46,XY. In
boys, testosterone production is often sufficient, but strict follow-up is warranted because of malig-
nancy risk, which appears inversely related to EMS. In girls, tumor risk is limited but gonads are not func-
tional,makinggonadectomythemostreasonableoption. (JClinEndocrinolMetab96:E1171–E1180,2011)
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Sex chromosome mosaicism (45,X/46,XY and vari-ants) occurs with an estimated incidence of 1.5 per
10,000 (1) and may be due to loss of the Y chromosome
through anaphase lag or to interchromosomal rearrange-
ments with final loss of a structurally abnormal Y chro-
mosome. The clinical spectrum is highly heterogeneous,
with no obvious correlation between the phenotypic ap-
pearance and the respective cell line counts on routine
peripheral blood karyotyping (1–3) or even on the basis of
gonadal cell line counts (4). Up to 95%of individualsmay
live undiagnosed as normal males (1). However, ambig-
uousgenitalia inanewbornbut alsomildundervirilization
(e.g. hypospadias) in boys or even typical Turner syn-
drome in girls may be associated with 45,X/46,XY mo-
saicism (3).
Individuals with 45,X/46,XY, as some other patients
with a disorder of sex development (DSD), more specifi-
cally thosewhohave (a specific part of) theYchromosome
in their karyotype (eventuallyonly at the gonadal level) are
at increased risk for the development of malignant germ
cell tumors (5, 6), referred to as type II germ cell tumors (7)
(see Ref. 8 for a review). This has been related to the pres-
ence and aberrant expression of the testis-specific protein
on Y (TSPY) gene, proximal on Yp (9–13).
The recent change in attitude toward clinical manage-
ment of DSD patients, with increased emphasis on a con-
servative approach, and the delay of irreversible surgery
until adulthood (14–17) has created doubt concerning the
optimal approach with regard to gonads at risk for ma-
lignant transformation, e.g. in individuals with 45,X/
46,XY mosaicism and male gender. Gonadectomy is not
the treatment of choice in these patients, but on the basis
of a review of the relevant literature, tumor risk in 45,X/
46,XY individuals has been reported to be around 15%
(8). However, clinical experience suggests a much lower
incidence in 45,X/46,XY Turner syndrome girls. On the
other hand, recent research has identified undifferentiated
gonadal tissue (UGT), for which 45,X/46,XY is a known
risk factor, as the precursor lesion for gonadoblastoma
(18, 19).More generally, on thebasis of pathological stud-
ies in gonadal samples from DSD patients, it has been
demonstrated that a disturbed process of gonadal devel-
opment, affecting Sertoli or granulosa cell differentiation
and function, results in insufficient microenvironmental
stimuli for the germ cells and hence in a delay or block in
their maturation. Immature germ cells are immunohisto-
chemically characterized by increased TSPY expression
and prolonged expression of embryonic germ cell mark-
ers, including the octamer binding transcription factor 3/4
(OCT3/4), encoded by the gene Pit-Oct-Unc domain class
5 transcription factor 1 (POU5F1) (18, 20–23), a condi-
tion that has been linked tomalignant transformation and
proliferation (13). The precise function of TSPY remains
unknown. However, its aberrant expression has been re-
lated to increased proliferation of germ cells and onco-
genic activity (10–12, 24–26). In embryonic stem cells,
OCT3/4 is involved in the maintenance of pluripotency
(27, 28), but in primordial germ cells, the experimental
data rather suggest a role in their survival (29). In this
context, the position of the OCT3/4 positive germ cells
within the testis tubule is of relevance: a luminal position
corresponds to simple maturation delay, whereas a posi-
tion on the basal lamina points at resistance to apoptosis
of a nonphysiological immature germ cell (20). Immuno-
histochemical staining for the c-KIT ligand stemcell factor
(SCF; also known as KITLG), which is of pathogenetic
relevance in the development of germ cell tumors (30, 31),
constitutes an important additional marker supporting
the differential diagnosis between maturation delay and
neoplastic transformation of germ cells because SCF pos-
itivity is consistently detected in carcinoma in situ (CIS),
gonadoblastoma, and testicular germ cell tumor but not in
testes with maturation delay (32, 33). Thus, recent re-
search has provided us with tools to detect not only the
early pathogenetic stages of CIS and gonadoblastoma but
also to identify premalignant lesions and germ cells at risk
for neoplastic transformation, allowing to predict tumor
development in gonadal biopsy samples and prophylacti-
cally removed gonads at a young age (8, 19, 33–35).
The present study was designed to refine our knowl-
edge on tumor risk in the highly heterogeneous condition,
which is 45,X/46,XY mosaicism. Specifically we exam-
ined whether a precise description of the clinical pheno-
type could be supportive in optimal patient management,
including gonadal surgery and follow-up for tumor risk.
Materials and Methods
Collection of gonadal samples and clinical data
Most samples (n 75, from 39 patients), obtained by biopsy
or gonadectomy, were retrieved from the archives of the pathol-
ogy departments of the ErasmusMedical Center Rotterdam, the
University Hospital Ghent, and the University Hospital Motol,
Prague. Samples were reviewed by M.C., J.P., and J.W.O., ex-
perienced in gonadal histology and germ cell tumor pathology.
The 45,X/46,XY mosaicism was diagnosed on the basis of rou-
tine karyotyping, in case of doubt, additional investigations
based on local protocols [fluorescence in situ hybridization
(FISH) with centromere Y probe, buccal smear chromosome
analysis, gonadal karyotpying by FISH]were used to confirm the
diagnosis. Patients were excluded if sufficient or reliable clinical
data were not available or if the diagnosis 45,X/46XY (or vari-
ants) mosaicism was uncertain. Clinical data were recorded by
the treating physicians (M.C., P.H., E.V.L., J.L., S.L.S.D., and
K.P.W.) and reviewed byM.C. and J.P. Additional samples (n
12, from nine patients) were obtained from referring centers;
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corresponding clinical data were provided by the treating pedi-
atric endocrinologists. Patients were classified into three groups,
based on the external masculinization score (EMS), which rep-
resents a clinical scoring system (based on the position of the
gonads, length of the phallus, presence of scrotal fusion, and
position of the urethral meatus) to quantitatively assess the
degree of undervirilization inDSDpatients (36). The EMSwas
calculated from data of the first clinical presentation: group 1,
mild undervirilization, EMS 7–12; group 2, ambiguous phe-
notype, EMS less than 7; and group 3, female phenotype,
representing in fact girls with Turner syndrome (without
clitoromegaly).
Immunohistochemical staining
Tissue fixation was performed with 10% formalin for 24 h,
followed by paraffin embedding and preparation of slices of 3
m thickness. For immunohistochemistry, heat-induced antigen
retrieval was applied in all stainings. OCT3/4 (Santa Cruz Bio-
technology, Santa Cruz, CA), dilution 1:350; for pretreatment
H2O2 for 5biotin blockingwas used; the incubation timewas
2 h at room temperature; the secondary antibody was biotinyl-
ated rabbit-antimouse. TSPY (kindly provided by Professor C.
Lau,Department ofMedicine, VAMedical Center, University of
California, San Francisco, CA) was used at a dilution of 1:3000;
incubation time was overnight at 4 C; the secondary antibody
was swine-antirabbit, biotin labeled. SCF (Santa Cruz Biotech-
nology) was used at a dilution of 1:350 to 1:500, with an incu-
bation time of overnight at 4 C; the secondary antibody was
hoarse-antigoat, biotin labeled. Detection was performed using
diaminobenzidine/H2O2 (OCT3/4) or New Fuchsin/Naphtol
ASMX phosphate (Sigma, Steinheim, Germany) (TSPY, SCF),
and counterstaining was with hematoxylin.
Microscopy and assessment of
tumor risk
Based on the general morphology, as as-
sessed on hematoxylin-eosin (HE) staining,
the samples were categorized as (dysge-
netic) testis, UGT, ovary, streak, or a com-
bination of these. The sample was consid-
ered to be at risk for germ cell tumor
development if either an in situ neoplastic
lesion (gonadoblastoma or CIS) or one or
more indices for premalignancy (UGT,
OCT3/4positive cells on thebasal laminaof
testis tubules, or positive SCF staining)were
present.
Statistical analysis
Results were analyzed with the SPSS
software (version 15.0; Chicago, IL), com-
parison of categorical variables was per-
formed using a Fisher exact test.
Ethics
The study was approved by the medical
ethical committees of the University Hospi-
tal Ghent (MEC 2008/098), the Erasmus
Medical Center Rotterdam (MEC 02.981),
and University Hospital Motol Prague (EC
237/09). The samples were used according
FIG. 1. A, Location of the gonads in the different phenotypic groups. Samples with an
unknown position contained no gonadal tissue on microscopic evaluation. B, Distribution of
the encountered gonadal differentiation patterns. C, Distribution of gonadal differentiation
patterns in the different phenotypic groups.








Patients 10 14 23
Gonadal samples 15 24 46
Biopsy 9 6
Gonadectomy 6 18 46
Sex of rearing
Male 10 10
Female 0 4 23
Mean age at surgery (yr) 4.0 2.2 12.2
EMS and sex of rearing unknown in one patient.
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to the Code for Proper Secondary Use of Human Tissue in The
Netherlands, as developed by the Dutch Federation of Medical
Scientific Societies (version 2002).
Results
An overview of the patients and samples is provided in
Table 1. The group of individuals with female pheno-
type is overrepresented, which probably relates to the
finding that most 45,X/46,XY cases live undiagnosed
(as normal males) (1). Surgery is delayed in this group
due to later diagnosis (mostly because of short stature)
than in groups with mild undervirilization and ambig-
uous phenotype.
In 16 of 87 samples (18.3%), no gonadal tissue was
found; hence, for these samples (further referred to as van-
ished), the gonadal position could not be determined.
In total, 84 gonadal samples were considered for fur-
ther analysis; one sample was excluded because it was a
gonadectomy specimen of a previously biopsied gonad
and revealed no new findings. In one patient who received
a left biopsy and a right gonadectomy, the EMS could not
be determinedbasedonavailable clinical information. For
the different phenotypic groups, the gonadal position, as
recorded during the biopsy/gonadectomy procedures, is
represented in Fig. 1A.
Figure 1B shows the prevalence of the various gonadal
differentiation patterns in our series, and Fig. 1C repre-
sents the distribution of these patterns within each phe-
notypic group.
Scrotal gonads were all recognized as testes. Gonads in
the inguinal position were mostly testes (72%), although
UGT (18%) and streak (9%) were also encountered. Ab-
dominal gonads mostly presented as streak tissue
(68.5%), but interestingly, testis (20.5%) or a combina-
tion of testisUGT (3.7%) is also possible. An abdominal
gonad with UGT differentiation was found in 5.6%, and
the only gonad with ovarian differentiation was in the
abdominal position (data not shown).
Figure 2 shows representative examples of the gonadal
differentiationpatterns thatwere encountered in the45,X/
46,XY individuals included in this study.
An in situ neoplasia, but no invasive tumor, was found
in four different patients (Table 2). One patient with an
EMS of 7.5 of 12 received prophylactic gonadectomy of a
right abdominal gonad, which on microscopic examina-
tion contained UGT with gonadoblastoma. On the left
side, a scrotal testis was present. One patient with an EMS
of only one of 12 received prophylactic surgery at the age
of 1 yr andwas found to have UGTwith gonadoblastoma
FIG. 2. Representative examples of the gonadal differentiation
patterns that were encountered in our series of patients with 45,X/
46,XY mosaicism. A, Normal testis, HE, 200. B, Dysgenetic testis
tubules, showing a thin basal lamina, an irregular tubular shape, and
increased stromal background, HE, 200. C, Streak, HE, 100. D,
Enlargement of C, clearly showing primitive testis cord-like structures
(arrows), HE, 200x. E, Ovarian follicles, encountered in only one
gonad in our series, HE, 200. F and G, UGT, HE, 200. H, Combined
pattern with testis (left) and UGT (right), HE, 100.
TABLE 2. Summary of gonads containing tumors or preneoplastic lesions in patients with 45,X/46,XY mosaicism,
taking into account the clinical phenotype
Mild
undervirilization Ambiguous phenotype Female phenotype Total
No risk 14 21 45 80
Tumor 1 2 1 4
Preneoplastic lesion 1 10 0 11
Riska 2/15 (13%) 12/23 (52%) 1/46 (2.2%) 15/84 (18%)
All tumors in our series were in situ germ cell neoplastic lesions, discovered after prophylactic gonadectomy. There were no invasive tumors. Tumor
risk was calculated from the presence of either an in situ neoplasia or preneoplastic changes, as described in Materials and Methods.
a P  0.001.
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in the left abdominal gonad; the right abdominal testis
displayed no neoplastic features. One patient (EMS 1.5 of
12) had a gonadoblastoma in a severely dysgenetic ingui-
nal testis; the right abdominal gonadwas a streak. Surgery
was performed at the age of 1 yr. The last patient was
diagnosed with Turner syndrome after work-up for de-
layed puberty.None of the treating physicians noticed any
clitoral enlargement. However, prophylactic gonadec-
tomy, performed at the age of 16 yr, revealed a testis con-
taining CIS in the right abdominal gonad, whereas the left
specimen contained no gonadal tissue.
Fifteen gonads, including the four with an in situ neo-
plastic lesion, in 12 different patients, displayed prema-
lignant characteristics. The prevalence of premalignant le-
sions was significantly different in the three groups (P 
0.001) and is represented inTable 2 andFig. 3A.The three
patients with bilateral premalignant lesions had an am-
biguous phenotype. Inguinal gonads displayed (pre)ma-
lignant characteristics more frequently compared with
scrotal or abdominal gonads; however, the difference was
not statistically significant (P  0.09) (Fig. 3B).
Clinical and hormonal data of individuals with at least
one preserved gonad or before gonadectomy were avail-
able in seven children, three pubertal boys, and one adult
man. These data (summarized in Table 3) suggest a mod-
erate to normal testosterone production in childhood and
no clear correlation between the EMS at first presentation
and testosterone levels. In the four (post) pubertal indi-
viduals, pubertal onset was spontaneous and progression
through puberty normal. The adult man is infertile but
testosterone levels are adequate without hormone
supplementation.
Discussion
Tumor risk has been estimated at 15% in 45,X/46,XY
individuals (8). However, in clinical practice, histological
examination of prophylactically re-
moved gonads in Turner girls with
45,X/46,XY suggests a much lower in-
cidence, whereas no data are available
for boys with 45,X/46,XY. Specifically
in this group, it is of interest to preserve
gonads to allow endogenous hormone
production and therefore spontaneous
puberty induction and maintenance. In
previous years, tools have been devel-
oped by our group to recognize germ
cells with premalignant characteristics,
such as a maturation delay or block of
germ cells, an immature environment,
and an increased potential to prolifer-
ate and to resist apoptosis (13, 18, 20–23, 32) (reviewed
in Refs. 7, 8, 19, 34, 35, and 37–39). It was shown that a
combination of these characteristics may lead to CIS or
gonadoblastoma, depending on the context of the mi-
croenvironment (18, 20, 40, 41). ForCIS, it has been dem-
onstrated that all cases will become invasive over a life-
time period (42); for gonadoblastoma this is less clear.
This study was undertaken to examine in a large series
of patients with 45,X/46,XY, clinically a very hetero-
geneous group, if the clinical phenotype reflects the go-
nadal phenotype and tumor risk, and whether this may
provide a tool in clinical practice to guide management
with regard to gonadal biopsy or gonadectomy in this
patient population.
The distribution of the respective cell lines as ob-
tained from peripheral blood karyotyping was not
taken into account for this study because previous ob-
servations revealed no correlation between peripheral
blood karyotype and gonadal karyotype or gonadal dif-
ferentiation patterns (4).
Morphological examination of the specimen revealed
some interesting findings. First, the absence of gonadal
tissue was observed frequently in our series (18%), as in
other causes of gonadal dysgenesis (M. Cools, unpub-
lished observation). Although theoretically it cannot be
excluded that the surgeon missed the gonad while per-
forming the gonadectomy procedure, this is unlikely, tak-
ing into account the frequency of this finding and the ex-
perience of the involved surgeons. Therefore, we
hypothesize a mechanism in which the gonadal anlage, if
unable to develop into a more mature stage, regresses by
apoptosis. Second, categorization of gonadal differentia-
tion patterns in 45,X/46,XY was difficult because they
represent a continuumbetween two extremes (normal tes-
tis and normal ovary) rather than easily determinable sep-
arate entities, as is shown in Fig. 2. Third, streak, defined
as nonfunctional gonadal tissue, or even UGT was often
FIG. 3. A, The presence of premalignant lesions or an in situ neoplasia in the gonads from
patients with 45,X/46,XY mosaicism, categorized according to their clinical phenotype. B,
Presence of premalignant lesions or an in situ neoplasia in gonads from patients with 45,X/
46,XY mosaicism, categorized according to the position of the gonad.
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referred to as ovarian-type stroma in official pathology
reports, probably due to the background of stromal cells.
However, the terminology of ovarian-type stromawas in-
terpret by some clinicians as ovarian tissue (defined by the
presence of follicles including germcells), eventually avail-
able for cryopreservation. In fact, irrespective of the clin-
ical phenotype, the finding of ovarian follicles was rare in
45,X/46,XY mosaicism (one of 87 samples), even from
tissue removed at a very young age. This is in contrast to
observations in 45,X and 45,X/46,XX gonads (43). Like-
wise, ovarian follicles in the context of an ovotestes (de-
fined as the copresence of testis and ovarian tissue, includ-
ing follicles, in one individual) were not encountered in
our population, unlike in 46,XX/46,XY chimerism (M.
Cools, unpublished observation). Streak tissue (in our se-
ries present in 44% of samples) by definition does not
contain germ cells, but also in dysgenetic testes and UGT,
germ cells were scarce. Increased apoptosis of germ cells
has been attributed to a defective microenvironment and
impaired meiosis of aneuploid germ cells (44).
Tumor risk was significantly reflected by the clinical
phenotype inour series (P0.001) and revealed tobe very
high (52%) in cases with an ambiguous phenotype. This
group had the highest prevalence of UGT (20.8%), which
has been recognized as the precursor lesion for gonado-
blastoma (18) (Fig. 1C).Moreover, testes, if present, were
severely dysgenetic in this group and often contained im-
matureOCT3/4-positive cells on the basal lamina, in con-
trast to patients with mild undervirilization, in whom
UGTwas less frequently observed (13.3%), and testes had
attained amoremature stage, with less pronounced shape
irregularity of the tubules and more frequent loss of
OCT3/4 expression in germ cells that had reached the
basal lamina. Moreover, testes were more often in the
scrotal position in this group (Fig. 1A). Cryptorchidism is
known as an independent risk factor for the development
of germ cell tumors (45), which has been related to mat-
uration delay of germ cells (46). This risk is probably
higher in inguinal than in abdominal gonads due to early
apoptosis of germ cells in the latter position (Ref. 47 and
TABLE 3. Summary of available clinical functional data in male patients with at least one preserved gonad or in
females before gonadectomy
Patient EMS Gonadal positiona Assessment T Remarks
Childhood
3 8.5 1 inguinal testis HCG, 3 yr 60 ng/dl (2.1 nmol/liter)b
1 scrotal testis HCG, 10 yr 54 ng/dl (1.9 nmol/liter)b
8 7.5 1 scrotal testis HCG, 1.5 yr 109 ng/dl (3.8 nmol/liter)b Test after unilateral
gonadectomy
14 1 1 abdominal testis HCG Good
1 abdominal UGT
28 4.5 1 abdominal testis HCG, 2 wk 140 ng/dl (4.8 nmol/liter)c
1 inguinal testis
35 4 1 abdominal testis T, 3 wk 135 ng/dl (4.7 nmol/liter)c Bilateral gonadectomy
and raised female
1 vanished gonad
37 5.5 1 inguinal testis T, 2 wk 172 ng/dl (6.0 nmol/liter)c
1 scrotal testis




2 11.5 1 inguinal testis PE P3G3, 6/6 ml No T suppletion
1 scrotal testis
5 8 1 scrotal testis (originally
inguinal)
PE, FSH, US, sperm
count
Nl pubertal development,
FSH1, infertility, Nl US
Actually 30 yr old, no
T suppletion
10 4.5 1 scrotal testis
(originally inguinal)
PE G2, 4 ml No T suppletion
12 1.5 1 scrotal testis PE, FSH Actually 15 yr old, no
T suppletion
Assay and age-specific baseline references (reference values after HCG were not available): T, Serum testosterone obtained after the functional
assessment; HCG, human chorion gonadotrophin test; PE, physical examination; US, Ultrasound; Nl, normal.
a At the moment of assessment.
b 8.6–14.4 ng/dl (0.3–0.5 nmol/liter).
c 14–363 ng/dl (0.5–12.6 nmol/liter).
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M. Cools, unpublished observation). In our study, ingui-
nal gonads revealed the highest tumor risk, but this was
not statistically significant,maybedue to small sample size
(Fig. 3B). Twenty percent of 45,X/46,XY testeswith spon-
taneous scrotal descent revealed premalignant character-
istics, but this number represents in fact only one of five
gonads, from an individual with an EMS of 5.5 and so
belonging to the ambiguous phenotype group. In inter-
preting these data, it has to be kept in mind that the dif-
ferentiation patterns in these gonads and the clinical phe-
notypes of the patients were very heterogeneous,
independently influencing tumor risk, in contrast to stud-
ies in patients with simple cryptorchidism. In the pheno-
typically female group, most gonads were streak or had
vanished, resulting in a low tumor risk (Table 1 and Fig.
1C). Only one of 46 gonads (2.2%), from a 16-yr-old girl
with Turner syndrome and a vanished gonad on the con-
tra-lateral side, displayed testis differentiation, notably
with CIS. Remarkably, no virilization, not even clitoral
enlargement, was noticed in this girl. The reason for the
discrepancy between this gonad and the 45 other samples
from this group remains unexplained.
The phenotype in all our patients revealed some de-
gree of undervirilization. Thus, due to selection bias
(obviously, no gonadal specimen
were available from individuals who
live undiagnosed), we are unable to
predict tumor risk in normal males
with a 45,X/46,XY constitution, rep-
resenting in fact the largest clinical
group (1). However, from our find-
ings as described above, it can be hy-
pothesized that in these individuals,
the risk is low because the clinical pic-
ture of a normal EMS score and bi-
laterally descended testes suggests a
(close to) normal testicular differen-
tiation and maturation process.
Moreover, the absence of reports in
the literature on testicular germ cell
tumors in males in whom a 45,X/
46,XY karyotype was unexpectedly
found is in line with this hypothesis.
Functional outcome data in males
with at least one preserved gonad were
scarce but suggest a sufficiently con-
served Leydig cell function to allow
spontaneous puberty, with, as ex-
pected, high FSH levels, predicting im-
paired Sertoli cell function, and infer-
tility (48). However, these preliminary
data emphasize the benefit for the male
45,X/46,XY individual if gonadectomy can be avoided.
Guidelines for conservative follow-up of these patients,
and for the timing and handling of testicular biopsies, are
waiting.
In 45,X/46,XY Turner girls, without signs of viriliza-
tion, tumor risk is low, but the gonadal tissue, if present,
in most cases is a nonfunctional streak, making the pres-
ervation of these gonads of no use. However, in cases in
which thegirl is very reluctant tohave surgery, or if surgery
is contraindicated, gonadectomy can be postponed with-
out great risk.
The question remainswhether, in cases of phenotypical
Turner syndromeandadiagnosis of45,Xmonosomyafter
routine cytogenetic analysis, additional investigations are
warranted to detect hiddenmosaicism. FISHanalysiswith
centromere X and Y probes on interphase nuclei, which is
reported to be superior to PCR in this context due to a
lower number of false-positive results, reveals an addi-
tional 46,XXcell line in 30%and a46,XYcell line in 10%
of cases (49). In view of this high number and in contrast
to previous suggestions (8), we currently subscribe to the
AmericanCollegeofMedicalGenetics guidelines, suggest-
ing routine screening for hidden mosaicism in all 45,X
women by additional FISH analysis on 200 interphase
FIG. 4. Suggested pathophysiology of germ cell tumor development in 45,X/46,XY gonads.
The EMS score quantitatively describes the patient’s phenotype. Higher EMS scores correlate
with a more advanced process of testis formation at the gonadal level. Disturbed gonadal
development, resulting from the abnormal karyotype, leads to impaired Sertoli/granulosa cell
function. Subsequently germ cells escape the normal control mechanisms exerted by the
supportive cell lineage (i.e. differentiation and mitotic or meiotic arrest), causing a delay or
block in their normal maturation process and leading to increased survival (prolonged OCT3/
4) and proliferation (increased TSPY) chances. Especially in gonads with a low degree of
testicularization, the four parameters required for malignant proliferation of germ cells are
present, leading to a high risk for the development of gonadoblastoma or CIS, depending on
the microenvironment and subsequently to an invasive germ cell tumor. PGC, Primordial germ
cell; GB, gonadoblastoma; GBY, gonadoblastoma region on Y; GCT, germ cell tumor.
[Adapted with permission from L. H. Looijenga et al.: Best Pract Res Clin Endocrinol Metab
24:291–310, 2010 (19). © Elsevier.]
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nuclei harvested from buccal smear (49). However, to re-
solve this long-standing question, we believe it is manda-
tory to report on tumor incidence in larger series of 45,X/
46,XY Turner women in whom even discrete signs of
virilization, pointing at the presence of some testicular
differentiation at the gonadal level, were explicitly sought
and excluded.
To summarize, our data suggest that the tumor risk in
45,X/46,XY patients is most pronounced in immature
and/or poorly differentiated gonadal tissue and that the
degree of testicularization of the gonad (defined as the
process of testicular development in its broadest sense) is
reflected by the clinical phenotype (19). This hypothesis
can modify our clinical approach to the 45,X/46,XY pa-
tient, resulting in an individualized management with re-
gard to tumor risk and gonadectomy (Fig. 4 and Table 4).
Future research and long-term follow-up of these patients
is necessary to demonstrate the safety and benefit of this
approach.
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